PM360_Trailblazer_2019   EDDIE_OZZIE_HM   PM360_Elite_2020   EDDIE_OZZIE_Winner   PM360_Trailblazer_2020   Inc_5000   PM360_Trailblazer_2021

Our Perspectives

Our Perspectives published on October 8, 2021
Navigation is a core, evidence-based strategy that performs as an all-encompassing eye of the entire community, healthcare systems, and provider organizations from the patient’s perspective. The navigation output delivers positive, measurable value in patient experience, clinical outcomes, and business performance or return on investment. It is a nationally recognized strategy to address health inequities across racial and ethnic minority populations to move the needle on cancer outcome disparities.
Our Perspectives published on August 27, 2020
PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries, recently named The Lynx Group’s toolkit, Patient Navigation in Cancer Care 2.0: Guiding patients to quality outcomes, as a Trailblazer Initiative finalist for Healthcare Provider (HCP) Education.
Our Perspectives published on August 19, 2020
Key Findings from the Real Time Market Intelligence (RTMi) engagements were incorporated into a brand strategic plan and disseminated to account managers at POA meeting and in training materials. The brand is now covered by Medicare and most commercial payers.
Our Perspectives published on January 29, 2020

With more therapies available than ever before and greater patient involvement in treatment decisions, oncology nurse navigators face the perennial challenge of providing high-quality patient and caregiver education in reader-friendly language.

Enter CONQUER: the patient voice. Published by The Lynx Group as the official publication of The Academy of Oncology Nurse & Patient Navigators (AONN+), this patient-facing magazine was launched in February 2015 to fill an unmet need for AONN+’s oncology nurse navigators.

Our Perspectives published on December 13, 2019
The recent proliferation of patient and caregiver support programs is being driven by greater patient involvement in health decisions, increasing attention on patient outcomes, and the growth of specialty drugs that require additional patient support. These programs encompass a range of services which enable pharmaceutical companies to improve access to, usage of, and adherence to prescription drug treatments.
Our Perspectives published on December 13, 2019
For decades, pharmaceutical companies have consulted with key healthcare providers (HCPs) and other key opinion leaders who have their finger on the pulse of the treatment landscape. In face-to-face interactions, HCPs have provided insight into a wide range of subjects related to a product or disease state.
Our Perspectives published on December 13, 2019
Each year, between 700,000 and 900,000 medical journal articles are added to the PubMed database managed by The U.S. National Library of Medicine. Many of these articles focus on key findings from biopharmaceutical research, conducted by companies that invest more than $70 billion annually in research and development of new therapies.

Results 1 - 7 of 7
 1249 South River Road, Suite 202A, Cranbury, NJ 08512
© The Lynx Group, LLC. All Rights Reserved.